Clarity Pharmaceuticals was featured in ATSE Focus magazine, a publication issued by the Australian Academy of Technology and Engineering (ATSE), which publishes articles, reviews and letters to address national technology issues and key policy issues – such as innovation and productivity. The article highlights the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine…
Clarity Pharmaceuticals’ partner, the Idaho Accelerator Center at Idaho State University, was awarded the Early Stage Innovation of the Year at the 2017 Idaho Innovation Awards. This achievement was for the development of a new and efficient process for producing copper-67. This process enables copper-67 to be manufactured in sufficient quantities and at a high quality…
Clarity Pharmaceuticals was featured in Nature’s MedTech Dealmakers, a publication dedicated to exploring the dealmaking trends of the growing medical technology industry. The article discussed Clarity’s most recent developments and highlighted the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine. Read the full article here: https://biopharmadealmakers.nature.com/users/37997-clarity-pharmaceuticals/documents/16507-clarity-pharmaceuticals-medtech-2017 Or as a PDF http://www.claritypharmaceuticals.com/wp-content/uploads/2017/05/Clarity-Pharmaceuticals-MedTech-2017.pdf…
Clarity Pharmaceuticals was featured in Biotech Dispatch, a publication dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector. The article highlighted Clarity’s expansion to Europe through the establishment of a subsidiary Company in Liège, Belgium, and the awarding of a local grant. Read the full article here: http://biotechdispatch.com.au/clarity-establishes-european-subsidiary/#sthash.vlRgoIh5.VDwTViUT.dpbs Or as…
Clarity Pharmaceuticals was featured in Pharma R&D Today by Elsevier, a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals. “We believe in personalized medicine and the development of new therapies that are more effective and have less side effects. At Clarity, we recognized that radiopharmaceuticals have this potential…
“Imaging technology is guiding cutting edge drug development.” Clarity Pharmaceuticals was featured in dealflow, the publication for the Entrepreneurs’ Programme which profiles some of the best performing and highest potential businesses that have received commercialisation support from the Australian Government. “Today’s biopharmaceutical companies are under pressure to meet the demand for more personalised therapies, where…
The latest article about Clarity Pharmaceuticals is in September’s Nature Biotechnology. Please contact us if you have any queries or interest in this area of radiopharmaceutical development. “Using positron emission tomography to visualize the distribution of a drug candidate in the entire body, Clarity Pharmaceuticals helps biopharmaceutical companies spend their money wisely on the most…
Clarity Pharmaceuticals was featured in an article in The Age about personalised medicine. “Dr Alan Taylor, a scientist and former investment banker, is now executive chairman of the Australian company Clarity Pharmaceuticals. Last month Clarity raised $1.1 million to further commercialise its personalised medicine companion diagnostic research. Clarity developed the technology to tag an antibody…
Australian incubator recognised as best in world ATP Innovations takes home top prizes at NBIA global awards in New Orleans Leading technology business incubator ATP Innovations took top honours today at the NBIA awards in New Orleans, Louisiana, winning the prestigious 2014 Randall M. Whaley Incubator of the Year Award at the International Conference on…
1 May 2014 Clarity Pharmaceuticals’ recent capital raising success was featured in BRW. Click below to read the article: “Biotech start-up Clarity Pharmaceuticals raises $1.1m on blue sky, backed with revenue“